Evaluating DMARDs for Rheumatoid Arthritis in Older Australians
VerifiedAdded on 2023/06/12
|7
|1276
|452
Report
AI Summary
This report examines the effectiveness of Disease-Modifying Antirheumatic Drugs (DMARDs) compared to Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in treating rheumatoid arthritis (RA) among older adults in Australia. The study addresses the problem of high RA prevalence in the Australian elderly population and aims to determine if DMARDs are a more effective intervention. Using a PICO framework, the research question focuses on whether DMARDs, such as Methotrexate, improve the condition of aged individuals with fewer side effects than NSAIDs, like Ibuprofen. The search strategy involved exploring databases like PubMed and CINAHL, utilizing MESH terms and keywords related to rheumatoid arthritis, DMARDs, and NSAIDs. The findings from selected articles suggest that DMARDs can slow disease progression and reduce bone and cartilage damage, although their action may not be as quick as NSAIDs. The report references studies that analyze the use of DMARDs in RA patients, including comparisons between elderly and younger patients, and the impact of combining DMARDs with TNF inhibitors. The overall conclusion points towards the potential benefits of DMARDs in managing RA in older adults, particularly when integrated with other treatments.
1 out of 7